<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044847</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC0901102</org_study_id>
    <secondary_id>ESR-16-12485</secondary_id>
    <nct_id>NCT03044847</nct_id>
  </id_info>
  <brief_title>The Cohort Study for Chronic Obstructive Pulmonary Disease (COPD) in China</brief_title>
  <official_title>The Cohort Study for Chronic Obstructive Pulmonary Diseases (COPD) in China---- Observation of the Disease Outcome and Identification of Prognostic Biomarkers for the Disease Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the large COPD cohort and biological database in&#xD;
      China, aiming for precision medicine to optimize diagnosis and treatment choices and to&#xD;
      monitor and improve clinical outcomes in this disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 5-year multi-center observational prospective longitudinal cohort study to to&#xD;
      establish the large COPD cohort and biological database in China, including COPD subjects( n=&#xD;
      3000) and GOLD 0 subjects (n= 800).Sites Investigators will be respiratory physicians working&#xD;
      in the respiratory department of our sites, which must be tier 2 or tier 3 hospitals in&#xD;
      China, with the equipment and ability to conduct pulmonary function test, HRCT.Patients must&#xD;
      meet all the inclusion criteria and none of the exclusion criteria.No additional&#xD;
      investigational drugs will be applied to the patients. Full analysis set will be used for all&#xD;
      analyses. Missing data will be analysed as it is. Statistical analysis will be conducted by&#xD;
      epidemiology &amp; statistics work group from Chinese Academy of Sciences, using SAS and SUDAAN&#xD;
      software. An electronic data capture system will be used in this study. Paper-based&#xD;
      questionnaire administration will also be used.Questionnaire variables will be checked before&#xD;
      data entry.During the study, PI will be in charge of the monitoring of the whole procedure.&#xD;
      Two working group will do the data cleaning and data analysing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>COPD-related mortality and all-cause mortality</measure>
    <time_frame>10 years</time_frame>
    <description>COPD-related mortality and all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COPD exacerbation rate per year</measure>
    <time_frame>10 years</time_frame>
    <description>COPD exacerbation rate per year</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3800</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>COPD group</arm_group_label>
    <description>The post-bronchodilator FEV1/FVC ratio &lt; 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GOLD 0 group</arm_group_label>
    <description>GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC â‰¥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COPD group</intervention_name>
    <description>The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.</description>
    <arm_group_label>COPD group</arm_group_label>
  </intervention>
  <biospec_descr>
    <textblock>
      whole blood and sputum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Tier 2 or tier 3 hospitals in China&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 40-75 years&#xD;
&#xD;
          -  COPD group: baseline post-bronchodilator FEV1/FVC &lt; 0.7&#xD;
&#xD;
          -  GOLD 0 group: individuals with chronic respiratory symptoms and/or high risk factors&#xD;
&#xD;
          -  Signed informed consent obtained prior to participations with the ability to comply&#xD;
             with protocol and be available for study visits over 5 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute exacerbation in the past 3 months&#xD;
&#xD;
          -  Having other respiratory diseases with massive lung tissue destruction such as severe&#xD;
             bronchiectasis and tuberculosis, etc&#xD;
&#xD;
          -  The usual criteria of serious uncontrolled diseases&#xD;
&#xD;
          -  thoracic or abdominal surgery in the last 3 months&#xD;
&#xD;
          -  eye surgery in the last three months&#xD;
&#xD;
          -  retinal detachment&#xD;
&#xD;
          -  myocardial infarction in the last 3 months&#xD;
&#xD;
          -  admission to hospital for any cardiac condition in the last month&#xD;
&#xD;
          -  heart rate over 120 beats per minute&#xD;
&#xD;
          -  antibacterial chemotherapy for tuberculosis&#xD;
&#xD;
          -  pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kewu Huang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Kewu Huang</investigator_full_name>
    <investigator_title>Professor/M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>no plan to share IPD</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03044847/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03044847/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

